Iterum Therapeutics plc (ITRMF) Cash from Operations (2017 - 2025)

Iterum Therapeutics has reported Cash from Operations for 9 years, with the latest figure at -$7.4 million in Q3 2025.

• On a quarterly basis, Cash from Operations fell 178.71% year-over-year to -$7.4 million in Q3 2025; TTM through Sep 2025 was -$19.5 million, a 44.81% increase from a year earlier, with the FY2024 full-year figure at -$26.8 million, up 31.93% from the prior year.
• Cash from Operations was -$7.4 million for Q3 2025 at Iterum Therapeutics, down from -$4.8 million in the prior quarter.
• The five-year high for Cash from Operations was -$1.1 million in Q1 2021, with the low at -$13.1 million in Q1 2024.
• Average Cash from Operations over 5 years is -$6.1 million, with a median of -$4.8 million recorded in 2025.
• The sharpest annual moves came in 2021 and 2023: Cash from Operations surged 95.87% in 2021, then tumbled 201.13% in 2023.
• Over 5 years, Cash from Operations stood at -$2.5 million in 2021, then sank by 73.44% to -$4.3 million in 2022, then sank by 201.13% to -$12.8 million in 2023, then surged by 66.86% to -$4.3 million in 2024, then tumbled by 74.98% to -$7.4 million in 2025.
• The last three Cash from Operations figures came in at -$7.4 million (Q3 2025), -$4.8 million (Q2 2025), and -$3.1 million (Q1 2025), per Business Quant data.